• news.cision.com/
  • RLS Global AB/
  • Presentation by Björn Larsson, CEO, RLS Global AB, about the company’s operations and the currently ongoing rights issue

Presentation by Björn Larsson, CEO, RLS Global AB, about the company’s operations and the currently ongoing rights issue

Report this content

Meet Björn Larsson, CEO of RLS Global AB, when he presents the company and the ongoing rights issue with a subscription period 28 October–11 November. The presentation was held at Redeye's latest investor event focusing on medtech on October 26.

Click here to watch the presentation in English (about 15 minutes long).

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget.

FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25

Eva Jagenheim, CFO, RLS Global
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global

Subscribe